318 related articles for article (PubMed ID: 25115504)
1. Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy.
Tian D; Kreeger PK
BMC Syst Biol; 2014 Aug; 8():98. PubMed ID: 25115504
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation.
Tian D; Mitchell I; Kreeger PK
BMC Syst Biol; 2016 Feb; 10():15. PubMed ID: 26861122
[TBL] [Abstract][Full Text] [Related]
3. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
Fujita M; Ieguchi K; Cedano-Prieto DM; Fong A; Wilkerson C; Chen JQ; Wu M; Lo SH; Cheung AT; Wilson MD; Cardiff RD; Borowsky AD; Takada YK; Takada Y
J Biol Chem; 2013 Jul; 288(27):19593-603. PubMed ID: 23696648
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.
Fujita M; Takada YK; Takada Y
J Biol Chem; 2013 Feb; 288(5):3059-69. PubMed ID: 23243309
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between integrin α6β4 and insulin-like growth factor-1 receptor (IGF1R) through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions.
Fujita M; Ieguchi K; Davari P; Yamaji S; Taniguchi Y; Sekiguchi K; Takada YK; Takada Y
J Biol Chem; 2012 Apr; 287(15):12491-500. PubMed ID: 22351760
[TBL] [Abstract][Full Text] [Related]
6. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
7. The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities.
Werner H
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834331
[TBL] [Abstract][Full Text] [Related]
8. IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.
Li Z; Pan W; Shen Y; Chen Z; Zhang L; Zhang Y; Luo Q; Ying X
Cell Cycle; 2018; 17(10):1212-1219. PubMed ID: 29886785
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth.
Shigyo M; Kuboyama T; Sawai Y; Tada-Umezaki M; Tohda C
Sci Rep; 2015 Jul; 5():12055. PubMed ID: 26170015
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor.
Spicer LJ; Aad PY
Biol Reprod; 2007 Jul; 77(1):18-27. PubMed ID: 17360960
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1.
Takada Y; Takada YK; Fujita M
Cytokine Growth Factor Rev; 2017 Apr; 34():67-72. PubMed ID: 28190785
[TBL] [Abstract][Full Text] [Related]
12. Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.
Cedano Prieto DM; Cheng Y; Chang CC; Yu J; Takada YK; Takada Y
PLoS One; 2017; 12(9):e0184285. PubMed ID: 28873464
[TBL] [Abstract][Full Text] [Related]
13. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ
J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468
[TBL] [Abstract][Full Text] [Related]
14. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer.
Wang K; Yu Y; Wang W; Jiang Y; Li Y; Jiang X; Qiao Y; Chen L; Zhao X; Liu J; Yang A; Li J; Zhang R
Oncogene; 2023 Mar; 42(14):1072-1087. PubMed ID: 36774408
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
16. Targeting the IGF1 axis in cancer proliferation.
Bruchim I; Attias Z; Werner H
Expert Opin Ther Targets; 2009 Oct; 13(10):1179-92. PubMed ID: 19663648
[TBL] [Abstract][Full Text] [Related]
17. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
18. The proximity-labeling technique BioID identifies sorting nexin 6 as a member of the insulin-like growth factor 1 (IGF1)-IGF1 receptor pathway.
Bareja A; Hodgkinson CP; Soderblom E; Waitt G; Dzau VJ
J Biol Chem; 2018 Apr; 293(17):6449-6459. PubMed ID: 29530981
[TBL] [Abstract][Full Text] [Related]
19. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
20. IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
Neuzillet Y; Chapeaublanc E; Krucker C; De Koning L; Lebret T; Radvanyi F; Bernard-Pierrot I
BMC Cancer; 2017 Sep; 17(1):636. PubMed ID: 28882129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
